Stryker (NYSE: SYK) has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, transitioning the operations to the newly formed VB Spine. The deal, originally announced in January, aligns with Stryker’s broader strategy to divest its spine implants businesses in international markets.
While financial terms were not disclosed, the transaction grants VB Spine exclusive access to Stryker’s Mako Spine and Copilot robotic technologies for use with its implants. Certain markets will transfer at later dates pending legal and regulatory approvals.
Kevin Lobo, Stryker’s chair and CEO, emphasized that the sale sharpens the company’s strategic focus, allowing greater investment in innovation and long-term growth. Stryker will maintain its presence in the spine sector through its Interventional Spine, Neurotechnology, and Enabling Technologies businesses, as well as a continued partnership with VB Spine.
Follow MEDWIRE.AI for more updates on medical technology advancements.
